Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians

Emergency Medicine International

Volumn 2016, Issue , 2016, Pages

  Peacock, W Frank ^a   Rafique, Zubaid ^a   Singer, Adam J ^b  

^a BEN TAUB GENERAL HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BLEEDING; BLEEDING TIME; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; EMERGENCY MEDICINE; EMERGENCY PHYSICIAN; HUMAN; LUNG EMBOLISM; NONVALVULAR ATRIAL FIBRILLATION; OUTPATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; VENOUS THROMBOEMBOLISM;

EID: 85041849572     PISSN: 20902840     EISSN: 20902859     Source Type: Journal    
DOI: 10.1155/2016/1781684     Document Type: Review

References (123)

1. J. J. Caro, "An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation," American Journal of Managed Care, vol. 10, no. 14, pp. S451-S461, 2004.
2. J. A. Heit, T. M. Petterson, S. A. Farmer, K. R. Balley, L. J. Melton III, "Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 35-year population-based study," ASH Annual Meeting Abstracts, vol. 108, p. 1488, 2006.
3. M. D. Silverstein, J. A. Heit, D. N. Mohr, T. M. Petterson, W. M. O'Fallon, L. J. Melton III, "Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study," Archives of Internal Medicine, vol. 158, no. 6, pp. 585-593, 1998.
4. P. P. Dobesh, "Economic burden of venous thromboembolism in hospitalized patients," Pharmacotherapy, vol. 29, no. 8, pp. 943-953, 2009.
5. C. J. Mercaldi, M. Ciarametaro, B. Hahn et al., "Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation," Stroke, vol. 42, no. 1, pp. 112-118, 2011.
6. C. Kearon, E. A. Akl, A. J. Comerota et al., "Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines," Chest, vol. 141, no. 2, pp. e419S-e494S, 2012.
7. C. Stellbrink, U. Nixdorff, T. Hofmann et al., "Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial," Circulation, vol. 109, no. 8, pp. 997-1003, 2004.
8. S. V. Rao and E. M. Ohman, "Anticoagulant therapy for percutaneous coronary intervention," Circulation: Cardiovascular Interventions, vol. 3, no. 1, pp. 80-88, 2010.
9. N. Martel, J. Lee, P. S. Wells, "Risk for heparin-induced thrombocytopenia with unfractionated and low-molecularweight heparin thromboprophylaxis: a meta-analysis," Blood, vol. 106, no. 8, pp. 2710-2715, 2005.
10. W. Ageno, A. S. Gallus, A. Wittkowsky, M. Crowther, E. M. Hylek, G. Palareti, "Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines," Chest, vol. 141, no. 2, pp. e44S-e88S, 2012.
11. J. Ansell, J. Hirsh, E. Hylek et al., "Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)," Chest, vol. 133, pp. 160S-198S, 2008.
12. L. Hamby, W. B. Weeks, C. Malikowski, "Complications of warfarin therapy: causes, costs, the role of the anticoagulation clinic," Effective Clinical Practice, vol. 3, no. 4, pp. 179-184, 2000.
13. ELIQUIS-, Bristol-Myers Squibb Company, Princeton, NJ, USA; Pfizer Inc., New York, NY, USA, 2015, http://packageinserts. bms. com/pi/pi eliquis. pdf.
14. PRADAXA-, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Conn, USA, 2015, http://docs. boehringer-ingelheim . com/Prescribing%20Information/PIs/Pradaxa/Pradaxa. pdf.
15. XARELTO-, Janssen Pharmaceuticals, Titusville, NJ,USA, 2015, https://www. xarelto-us. com/shared/product/xarelto/prescribing-information. pdf.
16. SAVAYSA-, Daiichi Sankyo Inc, Parsippany, NJ, USA, 2015, http://www. accessdata. fda. gov/drugsatfda docs/label/2015/206316lbl. pdf.
17. Lixiana-, Daiichi Sankyo Europe GmbH, Munich, Germany, 2015, https://www. medicines. org. uk/emc/PIL. 30504. latest. pdf.
18. Daiichi Sankyo, Daiichi Sankyo Launches LIXIANA(R) (edoxaban), a Direct Oral Factor Xa Inhibitor, in Japan for the Prevention of VenousThromboembolism after Major Orthopedic Surgery, Daiichi Sankyo, Tokyo, Japan, 2011, http://www. daiichisankyo. com/media investors/media relations/press releases/detail/005784. html.
19. S. J. Connolly, M. D. Ezekowitz, S. Yusuf et al., "Dabigatran versus warfarin in patients with atrial fibrillation," The New England Journal of Medicine, vol. 361, pp. 1139-1151, 2009.
20. R. P. Giugliano, C. T. Ruff, E. Braunwald et al., "Edoxaban versus warfarin in patients with atrial fibrillation," The New England Journal of Medicine, vol. 369, no. 22, pp. 2093-2104, 2013.
21. C. B. Granger, J. H. Alexander, J. J. McMurray et al., "Apixaban versus warfarin in patients with atrial fibrillation," The New England Journal of Medicine, vol. 365, pp. 981-992, 2011.
22. M. R. Patel, K. W. Mahaffey, J. Garg et al., "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation," The New England Journal of Medicine, vol. 365, no. 10, pp. 883-891, 2011.
23. C. T. Ruff, R. P. Giugliano, E. Braunwald et al., "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: ameta-analysis of randomised trials," The Lancet, vol. 383, no. 9921, pp. 955-962, 2014.
24. S. Chatterjee, P. Sardar, G. Biondi-Zoccai, D. J. Kumbhani, "New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesianmeta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation," JAMA Neurology, vol. 70, no. 12, pp. 1486-1490, 2013.
25. N. Mackman, "The role of tissue factor and factor VIIa in hemostasis," Anesthesia and Analgesia, vol. 108, no. 5, pp. 1447-1452, 2009.
26. J. Hirsh,V. Fuster, J. Ansell, J. L. Halperin, "AmericanHeart Association/American College of Cardiology Foundation guide to warfarin therapy," Circulation, vol. 107, no. 12, pp. 1692-1711, 2003.
27. J. Desai, J. M. Kolb, J. I. Weitz, J. Aisenberg, "Gastrointestinal bleeding with the new oral anticoagulants-defining the issues and the management strategies," Thrombosis and Haemostasis, vol. 110, no. 2, pp. 205-212, 2013.
28. M. S. Bathala, H. Masumoto, T. Oguma, L. He, C. Lowrie, J. Mendell, "Pharmacokinetics, biotransformation, mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans," Drug Metabolism and Disposition, vol. 40, no. 12, pp. 2250-2255, 2012.
29. G. Agnelli, H. R. Buller, A. Cohen et al., "Oral apixaban for the treatment of acute venous thromboembolism," The New England Journal of Medicine, vol. 369, no. 9, pp. 799-808, 2013.
30. R. Bauersachs, S. D. Berkowitz, B. Brenner et al., "Oral rivaroxaban for symptomatic venous thromboembolism," The New England Journal of Medicine, vol. 363, pp. 2499-2510, 2010.
31. H. R. Buller, H. Decousus, M. A. Grosso et al., "Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism,"The New England Journal of Medicine, vol. 369, pp. 1406-1415, 2013.
32. H. R. Buller, M. H. Prins, A. W. Lensin et al., "Oral rivaroxaban for the treatment of symptomatic pulmonary embolism," The New England Journal of Medicine, vol. 366, pp. 1287-1297, 2012.
33. S. Schulman, A. K. Kakkar, S. Z. Goldhaber et al., "Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis," Circulation, vol. 129, no. 7, pp. 764-772, 2014.
34. E. A. Nutescu, W. E. Dager, J. S. Kalus, J. J. Lewin, M. D. Cipolle, "Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations," American Journal of Health-System Pharmacy, vol. 70, no. 21, pp. 1914-1929, 2013.
35. PRAXBIND-, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Conn, USA, 2015, http://www. accessdata. fda. gov/drugsatfda docs/label/2015/761025lbl. pdf.
36. Thrombosis Canda, New/Noval Oral Anticoagulants (NOACs): Management of Bleeding, Thrombosis Canda, 2015, http://thrombosiscanada. ca/wp-content/uploads/2016/02/22 NOACs-Management-Bleeding 2016Jan12-FINAL. pdf.
37. Bleeding-Management in Patients Taking Oral Anticoagulants, Wirral University Teaching Hospital (NHS), 2016, http://www. wuth. nhs. uk/media/984539/Bleeding-Management-inpatients-taking-oral-anticoagulants-4-July-13. pdf.
38. D. M. Siegal, D. A. Garcia, M. A. Crowther, "How I treat target-specific oral anticoagulant-associated bleeding," Blood, vol. 123, no. 8, pp. 1152-1158, 2014.
39. A. C. Spyropoulos, "Reimbursement strategies in an outpatientbased disease management program for the treatment of deep venous thrombosis in an integrated health care system," Managed Care, vol. 8, supplement 1, pp. 14-20, 1999, http://www . managedcaremag. com/sites/default/files/supplements/9912 dvt suppl/9912. dvt. pdf.
40. J. D. Douketis, "Treatment of deep vein thrombosis: what factors determine appropriate treatment?" Canadian Family Physician, vol. 51, pp. 217-223, 2005.
41. J. I. Weitz and C. V. Pollack Jr., "Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants,"Thrombosis and Haemostasis, vol. 114, no. 6, pp. 1113-1126, 2015.
42. S. G. Goodman, D. M. Wojdyla, J. P. Piccini et al., "Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonismfor prevention of stroke and embolism trial in atrial fibrillation)," Journal of the American College of Cardiology, vol. 63, no. 9, pp. 891-900, 2014.
43. M. Shoeb and M. C. Fang, "Assessing bleeding risk in patients taking anticoagulants," Journal ofThrombosis andThrombolysis, vol. 35, no. 3, pp. 312-319, 2013.
44. J. A. Heit, "Venous thromboembolism: disease burden, outcomes and risk factors," Journal ofThrombosis and Haemostasis, vol. 3, no. 8, pp. 1611-1617, 2005.
45. V. Pengo, A. W. Lensing, M. H. Prins et al., "Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism," The New England Journal of Medicine, vol. 350, no. 22, pp. 2257-2264, 2004.
46. S. S. Adam, J. R. McDuffie, T. L. Ortel, J. W. Williams Jr., "Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review," Annals of Internal Medicine, vol. 157, no. 11, pp. 796-807, 2012.
47. R. Pisters, D. A. Lane, R. Nieuwlaat, C. B. de Vos, H. J. Crijns, G. Y. Lip, "A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey," Chest, vol. 138, no. 5, pp. 1093-1100, 2010.
48. S. G. Aller, J. Yu, A. Ward et al., "Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding," Science, vol. 323, no. 5922, pp. 1718-1722, 2009.
49. L. C. Quattrochi and P. S. Guzelian, "CYP3A regulation: from pharmacology to nuclear receptors," Drug Metabolism and Disposition, vol. 29, no. 5, pp. 615-622, 2001.
50. C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob, A. J. Comerota, "Antithrombotic therapy for venous thromboembolic disease: AmericanCollege ofChest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)," Chest, vol. 133, no. 6, pp. 454S-545S, 2008.
51. K. Babilonia and T. Trujillo, "The role of prothrombin complex concentrates in reversal of target specific anticoagulants," Thrombosis Journal, vol. 12, article 8, 2014.
52. E. Gehrie and C. Tormey, "Novel oral anticoagulants: efficacy, laboratory measurement, approaches to emergent reversal," Archives of Pathology and Laboratory Medicine, vol. 139, no. 5, pp. 687-692, 2015.
53. A. M. Winkler and C. A. Tormey, "Pathology consultation on monitoring direct thrombin inhibitors and overcoming their effects in bleeding patients," The American Journal of Clinical Pathology, vol. 140, no. 5, pp. 610-622, 2013.
54. J. Curvers, D. van de Kerkhof, A. K. Stroobants, E.-J. van den Dool, V. Scharnhorst, "Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?" American Journal of Clinical Pathology, vol. 138, no. 4, pp. 551-558, 2012.
55. D. D. Castellone and E. M. Van Cott, "Laboratorymonitoring of new anticoagulants," American Journal of Hematology, vol. 85, no. 3, pp. 185-187, 2010.
56. R. C. Gosselin, D. M. Dwyre, W. E. Dager, "Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay," Annals of Pharmacotherapy, vol. 47,no. 12, pp. 1635-1640, 2013.
57. W. Mueck, S. Schwers, J. Stampfuss, "Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring," Thrombosis Journal, vol. 11, article 10, 2013.
58. M. A. Miyares and K. Davis, "Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient," American Journal of Health-System Pharmacy, vol. 69, no. 17, pp. 1473-1484, 2012.
59. T. Baglin, "The role of the laboratory in treatment with new oral anticoagulants," Journal ofThrombosis and Haemostasis, vol. 11, supplement 1, pp. 122-128, 2013.
60. D. Garcia, Y. C. Barrett, E. Ramacciotti, J. I. Weitz, "Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants," Journal of Thrombosis and Haemostasis, vol. 11, no. 2, pp. 245-252, 2013.
61. J. Douxfils, F. Mullier, C. Loosen, C. Chatelain, B. Chatelain, J.-M. Dogné, "Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature," Thrombosis Research, vol. 130, no. 6, pp. 956-966, 2012.
62. Y. Morishima and C. Kamisato, "Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, thrombin generation assay," American Journal of Clinical Pathology, vol. 143, no. 2, pp. 241-247, 2015.
63. E. S. Eerenberg, P. W. Kamphuisen, M. K. Sijpkens, J. C. Meijers, H. R. Buller, M. Levi, "Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects," Circulation, vol. 124, no. 14, pp. 1573-1579, 2011.
64. R. Herrmann, J. Thom, A. Wood, M. Phillips, S. Muhammad, R. Baker, "Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban," Thrombosis and Haemostasis, vol. 111, no. 5, pp. 989-995, 2014.
65. A. Tripodi, L. Padovan, C. Veena, E. Scalambrino, S. Testa, F. Peyvandi, "How the direct oral anticoagulant apixaban affects thrombin generation parameters," Thrombosis Research, vol. 135, no. 6, pp. 1186-1190, 2015.
66. H. Zahir, K. S. Brown, A. G. Vandell et al., "Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate," Circulation, vol. 131, no. 1, pp. 82-90, 2015.
67. L. M. Asmis, L. Alberio, A. Angelillo-Scherrer et al., "Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 swiss laboratories," Thrombosis Research, vol. 129, no. 4, pp. 492-498, 2012.
68. Y. C. Barrett, Z. Wang, C. Frost, A. Shenker, "Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay," Thrombosis and Haemostasis, vol. 104, no. 6, pp. 1263-1271, 2010.
69. A. Cuker and H. Husseinzadeh, "Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review," Journal of Thrombosis andThrombolysis, vol. 39, no. 3, pp. 288-294, 2015.
70. D. M. Adcock and R. Gosselin, "Direct oral anticoagulants (DOACs) in the laboratory: 2015 review," Thrombosis Research, vol. 136, no. 1, pp. 7-12, 2015.
71. J. H. Levy, W. Ageno, N. C. Chan,M. Crowther, P. Verhamme, J. I. Weitz, "When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH," Journal ofThrombosis andHaemostasis, vol. 14, no. 3, pp. 623-627, 2016.
72. M. Makris, J. J. Van Veen, C. R. Tait, A. D. Mumford, M. Laffan, "Guideline on the management of bleeding in patients on antithrombotic agents," British Journal of Haematology, vol. 160, no. 1, pp. 35-46, 2013.
73. D. A. Garcia and M. A. Crowther, "Reversal of warfarin: casebased practice recommendations," Circulation, vol. 125, no. 23, pp. 2944-2947, 2012.
74. R. I. Baker, P. B. Coughlin, A. S. Gallus, P. L. Harper, H. H. Salem, E. M. Wood, "Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis," TheMedical Journal of Australia, vol. 181, no. 9, pp. 492-497, 2004.
75. M. Makris and H. G. Watson, "The management of coumarininduced over-anticoagulation Annotation," British Journal of Haematology, vol. 114, no. 2, pp. 271-280, 2001.
76. D. F. O'Shaughnessy, C. Atterbury, P. Bolton Maggs et al., "Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant," British Journal of Haematology, vol. 126, no. 1, pp. 11-28, 2004.
77. M. Zareh, A. Davis, S. Henderson, "Reversal of warfarininduced hemorrhage in the emergency department," Western Journal of Emergency Medicine, vol. 12, no. 4, pp. 386-392, 2011.
78. S. Pandey and G. N. Vyas, "Adverse effects of plasma transfusion," Transfusion, vol. 52, supplement 1, pp. 65S-79S, 2012.
79. M. Makris, M. Greaves, W. S. Phillips, S. Kitchen, F. R. Rosendaal, F. E. Preston, "Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy," Thrombosis and Haemostasis, vol. 77, no. 3, pp. 477-480, 1997.
80. S. Schulman and N. R. Bijsterveld, "Anticoagulants and their reversal," TransfusionMedicine Reviews, vol. 21, no. 1, pp. 37-48, 2007.
81. KCENTRA-, CSL Behring, King of Prussia, Pa, USA, 2013, http://www. fda. gov/ucm/groups/fdagov-public/@fdagov-biogen/documents/document/ucm350239. pdf.
82. R. Sarode, T. J. Milling, M. A. Refaai et al., "Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase iiib study," Circulation, vol. 128, no. 11, pp. 1234-1243, 2013.
83. A. Majeed, H.-G. Hwang, S. J. Connolly et al., "Management and outcomes of major bleeding during treatment with dabigatran or warfarin," Circulation, vol. 128, no. 21, pp. 2325-2332, 2013.
84. C. Held, E. M. Hylek, J. H. Alexander et al., "Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial," European Heart Journal, vol. 36, no. 20, pp. 1264-1272, 2015.
85. J. P. Piccini, J. Garg, M. R. Patel et al., "Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial," European Heart Journal, vol. 35, no. 28, pp. 1873-1880, 2014.
86. J. Skaistis and T. Tagami, "Risk of fatal bleeding in episodes of major bleeding with new oral anticoagulants and vitamin k antagonists: a systematic review and meta-analysis," PLoS ONE, vol. 10, no. 9, Article ID e0137444, 2015.
87. C. T. January, L. S. Wann, J. S. Alpert et al., "2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society," Journal of the American College of Cardiology, vol. 64, no. 21, pp. e1-e76, 2014.
88. D. Faraoni, J. H. Levy, P. Albaladejo, C. Samama, "Updates in the perioperative and emergency management of nonvitamin K antagonist oral anticoagulants," Critical Care, vol. 19, article 203, 2015.
89. G. Breuer, D. R. Weiss, J. Ringwald, "'New' direct oral anticoagulants in the perioperative setting," Current Opinion in Anaesthesiology, vol. 27, no. 4, pp. 409-419, 2014.
90. R. Ferrandis, J. Castillo, J. de Andrés et al., "The perioperative management of new direct oral anticoagulants: a question without answers," Thrombosis and Haemostasis, vol. 110, no. 3, pp. 515-522, 2013.
91. W. I. Gonsalves, R. K. Pruthi, M. M. Patnaik, "The new oral anticoagulants in clinical practice,"Mayo Clinic Proceedings, vol. 88, no. 5, pp. 495-511, 2013.
92. K. Ogata, J. Mendell-Harary, M. Tachibana et al., "Clinical safety, tolerability, pharmacokinetics, pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers," Journal of Clinical Pharmacology, vol. 50, no. 7, pp. 743-753, 2010.
93. D. A. Parasrampuria, T. Marbury, N. Matsushima et al., "Pharmacokinetics, safety, tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis," Thrombosis and Haemostasis, vol. 113, no. 4, pp. 719-727, 2015.
94. J. van Ryn, J. Stangier, S. Haertter et al., "Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity," Thrombosis and Haemostasis, vol. 103, no. 6, pp. 1116-1127, 2010.
95. M. Levi, K. T. Moore, C. F. Castillejos et al., "Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers," Journal ofThrombosis andHaemostasis, vol. 12, no. 9, pp. 1428-1436, 2014.
96. R. Marlu, E. Hodaj, A. Paris, P. Albaladejo, J. L. Crackowski, G. Pernod, "Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers," Thrombosis and Haemostasis, vol. 108, no. 2, pp. 217-224, 2012.
97. G. Escolar, V. Fernandez-Gallego, E. Arellano-Rodrigo et al., "Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood," PLoS ONE, vol. 8, no. 11, Article ID e78696, 2013.
98. T. Fukuda, Y. Honda, C. Kamisato, Y. Morishima, T. Shibano, "Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents," Thrombosis and Haemostasis, vol. 107, no. 2, pp. 253-259, 2012.
99. FEIBA, Baxter Healthcare Corporation,Westlake Village, Calif, USA, 2013, http://www. fda. gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM221749. pdf.
100. R. Alikhan, R. Rayment, D. Keeling et al., "The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran," Emergency Medicine Journal, vol. 31, no. 2, pp. 163-168, 2014.
101. H. Shakur, I. Roberts, R. Bautista et al., "Effects of tranexamic acid on death, vascular occlusive events, blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial," The Lancet, vol. 376, no. 9734, pp. 23-32, 2010.
102. A. Clavé, F. Fazilleau, D. Dumser, J. Lacroix, "Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: a casecontrol study in 70 patients," Orthopaedics and Traumatology: Surgery and Research, vol. 98, no. 5, pp. 484-490, 2012.
103. C. V. Pollack Jr., P. A. Reilly, J. Eikelboom et al., "Idarucizumab for dabigatran reversal," The New England Journal of Medicine, vol. 373, pp. 511-520, 2015.
104. S. Hollenbach, G. Lu, F. DeGuzman et al., "Abstract 14657: andexanet-alfa and PER977 (Arapazine) correct blood loss in a rabbit liver lacerationmodel-only andexanet reverses markers of fXa-mediated anticoagulation," Circulation, vol. 130, abstract A14657, 2014.
105. A. Gómez-Outes, M. L. Suárez-Gea, R. Lecumberri, A. I. Terleira-Fernández, E. Vargas-Castrillón, "Specific antidotes in development for reversal of novel anticoagulants: a review," Recent Patents on Cardiovascular Drug Discovery, vol. 9, no. 1, pp. 2-10, 2014.
106. J. E. Ansell, S. H. Bakhru, B. E. Laulicht et al., "Use of PER977 to reverse the anticoagulant effect of edoxaban," The New England Journal of Medicine, vol. 371, no. 22, pp. 2141-2142, 2014.
107. G. Lu, F. R. DeGuzman, S. J. Hollenbach et al., "A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa," Nature Medicine, vol. 19,no. 4, pp. 446-451, 2013.
108. D. M. Siegal and A. Cuker, "Reversal of target-specific oral anticoagulants," Drug Discovery Today, vol. 19, no. 9, pp. 1465-1470, 2014.
109. A. M. Gold, M. Crowther, G. Levy et al., "ANNEXA-R: a phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of rivaroxaban-induced anticoagulation in older subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors," Journal of the American College of Cardiology, vol. 65, no. 10, article A23, 2015.
110. M. Crowther, G. G. Levy, G. Lu et al., "ANNEXA-A: a phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of apixaban-induced anticoagulation in older subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors," in Proceedings of the American Heart Association Scientific Sessions "Clinical Science: Special Reports", Chicago, Ill, USA, November 2014.
111. M. Franchini and G. Lippi, "Prothrombin complex concentrates: an update," Blood Transfusion, vol. 8, no. 3, pp. 149-154, 2010.
112. A.-C. Martin, B. Le Bonniec, A.-M. Fischer et al., "Evaluation of recombinant activated factor VII, prothrombin complex concentrate, fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis," International Journal of Cardiology, vol. 168, no. 4, pp. 4228-4233, 2013.
113. J. Biskupiak, S. R. Ghate, T. Jiao, D. Brixner, "Cost implications of formulary decisions on oral anticoagulants in nonvalvular atrial fibrillation," Journal of Managed Care Pharmacy, vol. 19, no. 9, pp. 789-798, 2013.
114. M. F. Bullano, V. Willey, O. Hauch, G. Wygant, A. C. Spyropoulos, L. Hoffman, "Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization," Journal ofManaged Care Pharmacy, vol. 11, no. 8, pp. 663-673, 2005.
115. A. Amin, A. Bruno, J. Trocio, J. Lin, M. Lingohr-Smith, "Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with nonvalvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US," Journal of Medical Economics, vol. 18, no. 6, pp. 399-409, 2015.
116. S. M. Singh and H. C. Wijeysundera, "Cost-effectiveness of novel oral anticoagulants for stroke prevention in non-valvular atrial fibrillation," Current Cardiology Reports, vol. 17, article 61, 2015.
117. A. Maan, E. K. Heist, J. N. Ruskin, M. Mansour, "Practical issues in the management of novel oral anticoagulantscardioversion and ablation," Journal of Thoracic Disease, vol. 7, no. 2, pp. 115-131, 2015.
118. F. Lozano, J. Trujillo-Santos, M. Barrón et al., "Home versus in-hospital treatment of outpatients with acute deep venous thrombosis of the lower limbs," Journal of Vascular Surgery, vol. 59, no. 5, pp. 1362. e1-1367. e1, 2014.
119. D. Aujesky, P.-M. Roy, F. Verschuren et al., "Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, noninferiority trial," The Lancet, vol. 378, no. 9785, pp. 41-48, 2011.
120. D. M. Beam, Z. P. Kahler, J. A. Kline, "Immediate discharge and home treatment with rivaroxaban of low-risk venous thromboembolism diagnosed in two U. S. emergency departments: a one-year preplanned analysis," Academic Emergency Medicine, vol. 22, no. 7, pp. 788-795, 2015.
121. I. M. van Korlaar, C. Y. Vossen, F. R. Rosendaal et al., "The impact of venous thrombosis on quality of life," Thrombosis Research, vol. 114, no. 1, pp. 11-18, 2004.
122. C. L. Marvig, T. I. Verhoef, A. de Boer et al., "Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants," Thrombosis Research, vol. 136, no. 1, pp. 69-75, 2015.
123. B. U. Monz, S. J. Connolly, M. Korhonen, H. Noack, J. Pooley, "Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study," International Journal of Cardiology, vol. 168, no. 3, pp. 2540-2547, 2013.